The global burden of diabetes-related chronic kidney disease from 1990 to 2021, with projections to 2036

Abstract

Aim: Diabetes-related chronic kidney disease (CKD) is a major cause of both CKD and end-stage renal disease. This study aimed to examine updated global trends in the burden of diabetes-related CKD from 1990 to 2021, stratified by location, age, and sex.

Methods: Using data from the Global Burden of Disease (GBD) 2021 dataset, we quantified the burden of CKD worldwide, including prevalence, incidence, mortality, and disability-adjusted life years (DALYs).

Results: From 1990 to 2021, global surveillance revealed a persistent increase in the burden of diabetes-related CKD, with age-standardized incidence rates (ASIRs) rising significantly across socio-demographic index (SDI) quintiles. Forecasted ASIR for type 2 diabetes-related CKD (T2D-CKD) shows a consistent pattern of escalation, whereas type 1 diabetes-related CKD (T1D-CKD) is expected to decrease from 2021 to 2036. Across all SDI quintiles, ASIR for diabetes-related CKD increased progressively, with high-SDI regions showing the highest rates. Moreover, the global DALY burden peaked in the 50-54 age group for T1D-CKD and in the 65-69 age group for T2D-CKD in the Southeast Asia, East Asia, and Oceania super-region. Overall, the burden of diabetes-related CKD was higher in males, while the prevalence of T1D-CKD was higher in females.

Conclusion: The global burden of diabetes-related CKD increased substantially between 1990 and 2021 across diverse geographic regions. Target strategies are urgently needed to reduce the burden of diabetes-related CKD and address this growing public health challenge.

Keywords

Diabetes-related chronic kidney disease / incidence / prevalence / mortality / disability-adjusted life years

References

[1] 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021.Lancet2023;402:203-34 PMCID:PMC10364581

[2] Katsarou A,Rawshani A.Type 1 diabetes mellitus.Nat Rev Dis Primers2017;3:17016

[3] Ahmad AA,Rosca M.Mitochondria in diabetic kidney disease.Cells2021;10:2945 PMCID:PMC8616075

[4] Dong Z,Pan S.A multimodal transformer system for noninvasive diabetic nephropathy diagnosis via retinal imaging.NPJ Digit Med2025;8:50 PMCID:PMC11759696

[5] Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.Lancet2020;395:709-33 PMCID:PMC7049905

[6] Gupta S,Golestaneh L.Diabetic kidney disease: an update.Med Clin North Am2023;107:689-705

[7] Carlsson LM,Jacobson P.The incidence of albuminuria after bariatric surgery and usual care in Swedish Obese Subjects (SOS): a prospective controlled intervention trial.Int J Obes2015;39:169-75 PMCID:PMC4285618

[8] Yim HE.Obesity and chronic kidney disease: prevalence, mechanism, and management.Clin Exp Pediatr2021;64:511-8 PMCID:PMC8498012

[9] Deng Y,Wu Y.Global, regional, and national burden of diabetes-related chronic kidney disease from 1990 to 2019.Front Endocrinol2021;12:672350 PMCID:PMC8281340

[10] Piani F,Tommerdahl KL.Sex-related differences in diabetic kidney disease: a review on the mechanisms and potential therapeutic implications.J Diabetes Complications2021;35:107841 PMCID:PMC8007279

[11] Giandalia A,Gembillo G.Gender differences in diabetic kidney disease: focus on hormonal, genetic and clinical factors.Int J Mol Sci2021;22:5808 PMCID:PMC8198374

[12] Liu W,Wang R.Global trends in the burden of chronic kidney disease attributable to type 2 diabetes: an age-period-cohort analysis.Diabetes Obes Metab2024;26:602-10

[13] Dai H,Chalghaf N,Bragazzi NL.The global burden of disease attributable to high body mass index in 195 countries and territories, 1990-2017: an analysis of the Global Burden of Disease Study.PLoS Med2020;17:e1003198 PMCID:PMC7386577

[14] 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.Lancet2018;392:1923-94 PMCID:PMC6227755

[15] 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019.Lancet2020;396:1160-203 PMCID:PMC7566045

[16] 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.Lancet2018;392:1789-858 PMCID:PMC6227754

[17] Xie J,Long Z.Global burden of type 2 diabetes in adolescents and young adults, 1990-2019: systematic analysis of the Global Burden of Disease Study 2019.BMJ2022;379:e072385 PMCID:PMC9727920

[18] 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.Lancet2020;396:1204-22 PMCID:PMC7567026

[19] Li Y,Shen B.Temporal trends in prevalence and mortality for chronic kidney disease in China from 1990 to 2019: an analysis of the Global Burden of Disease Study 2019.Clin Kidney J2023;16:312-21 PMCID:PMC9900593

[20] Xie D,Cui H.Global burden and influencing factors of chronic kidney disease due to type 2 diabetes in adults aged 20-59 years, 1990-2019.Sci Rep2023;13:20234 PMCID:PMC10658077

[21] Wang Y,Lu J.Trends and analysis of risk factor differences in the global burden of chronic kidney disease due to type 2 diabetes from 1990 to 2021: a population-based study.Diabetes Obes Metab2025;27:1902-19

[22] Unnikrishnan R,Mohan V.Diabetes in South Asians: is the phenotype different?.Diabetes2014;63:53-5

[23] Qiao Q, Hu G, Tuomilehto J, et al; DECODA Study Group. Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diabetes Care. 2003;26:1770-80.

[24] Chandie Shaw PK,van Es LA.South-Asian type 2 diabetic patients have higher incidence and faster progression of renal disease compared with Dutch-European diabetic patients.Diabetes Care2006;29:1383-5

[25] Noble JA.Genetics of the HLA region in the prediction of type 1 diabetes.Curr Diab Rep2011;11:533-42 PMCID:PMC3233362

[26] de Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL; PREVEND study group. Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord. 2002;26 Suppl 4:S21-4.

[27] Foster MC,Larson MG.Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study.Am J Kidney Dis2008;52:39-48 PMCID:PMC2531220

[28] Østergaard MV,Christensen M.Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease.Am J Physiol Renal Physiol2021;321:F149-61

[29] Perry HM Jr,Fornoff JR.Early predictors of 15-year end-stage renal disease in hypertensive patients.Hypertension1995;25:587-94

[30] Hustrini NM,Rotmans JI.Prevalence and risk factors for chronic kidney disease in Indonesia: an analysis of the National Basic Health Survey 2018.J Glob Health2022;12:04074 PMCID:PMC9559178

[31] Shepard BD.Sex differences in diabetes and kidney disease: mechanisms and consequences.Am J Physiol Renal Physiol2019;317:F456-62 PMCID:PMC6732459

[32] Carrero JJ.Gender differences in chronic kidney disease: underpinnings and therapeutic implications.Kidney Blood Press Res2010;33:383-92

[33] Kautzky-Willer A,Pacini G.Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus.Endocr Rev2016;37:278-316 PMCID:PMC4890267

[34] Liu D,Zhou Y.Sex-specific associations between skeletal muscle mass and incident diabetes: a population-based cohort study.Diabetes Obes Metab2024;26:820-8

[35] Kovesdy CP.Epidemiology of chronic kidney disease: an update 2022.Kidney Int Suppl2022;12:7-11 PMCID:PMC9073222

[36] Muthuppalaniappan VM.Ethnic/race diversity and diabetic kidney disease.J Clin Med2015;4:1561-5 PMCID:PMC4555076

[37] Hayanga B,Bécares L.Ethnic inequalities in multiple long-term health conditions in the United Kingdom: a systematic review and narrative synthesis.BMC Public Health2023;23:178 PMCID:PMC9879746

[38] Insaf TZ,Yucel RM,Shaw BA.Associations between race, lifecourse socioeconomic position and prevalence of diabetes among US women and men: results from a population-based panel study.J Epidemiol Community Health2014;68:318-25

[39] Jadawji C,Gillies C.Prevalence and progression of diabetic nephropathy in South Asian, white European and African Caribbean people with type 2 diabetes: a systematic review and meta-analysis.Diabetes Obes Metab2019;21:658-73

[40] Genovese G,Ross MD.Association of trypanolytic ApoL1 variants with kidney disease in African Americans.Science2010;329:841-5 PMCID:PMC2980843

[41] Hundemer GL,Norman PA.Performance of the 2021 race-free CKD-EPI creatinine- and cystatin C-based estimated GFR equations among kidney transplant recipients.Am J Kidney Dis2022;80:462-72.e1

[42] Hsu CY.CKD-EPI eGFR categories were better than MDRD categories for predicting mortality in a range of populations.Ann Intern Med2012;157:JC5-12